DiaMedica Therapeutics (NASDAQ:DMAC) Issues Quarterly Earnings Results

DiaMedica Therapeutics (NASDAQ:DMAC) released its earnings results on Monday. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01, FiscalAI reports.

DiaMedica Therapeutics Trading Down 1.5%

NASDAQ DMAC traded down $0.10 on Monday, reaching $6.65. 180,586 shares of the company were exchanged, compared to its average volume of 204,830. The business’s fifty day moving average price is $6.60 and its 200 day moving average price is $6.95. The stock has a market capitalization of $358.30 million, a P/E ratio of -9.37 and a beta of 1.01. DiaMedica Therapeutics has a fifty-two week low of $4.39 and a fifty-two week high of $10.42.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. acquired a new stake in DiaMedica Therapeutics during the third quarter worth about $27,000. Bank of America Corp DE boosted its holdings in DiaMedica Therapeutics by 3,710.3% in the 2nd quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock valued at $33,000 after purchasing an additional 8,274 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in DiaMedica Therapeutics in the 2nd quarter valued at about $49,000. Invesco Ltd. purchased a new stake in shares of DiaMedica Therapeutics in the 2nd quarter valued at approximately $54,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of DiaMedica Therapeutics in the 2nd quarter valued at approximately $56,000. Institutional investors and hedge funds own 10.12% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Wall Street Zen raised shares of DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Friday, July 17th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, DiaMedica Therapeutics has an average rating of “Moderate Buy” and an average target price of $12.00.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.